Board Member
Collegium Pharmaceutical, Inc (COLL)Equibles does not estimate personal net worth.
Get an email with a short summary when Collegium Pharmaceutical, Inc publishes a filing, an earnings call transcript or a press release.
Get COLL alertsVikram Karnani is recorded as Board Member at Collegium Pharmaceutical, Inc (COLL) since November 12, 2024 and CEO at Collegium Pharmaceutical, Inc (COLL). Collegium Pharmaceutical, Inc reported in an 8-K filed May 19, 2025 that Vikram Karnani was appointed Director, effective May 15, 2025. Collegium Pharmaceutical, Inc reported in an 8-K filed November 7, 2024 that Vikram Karnani was appointed member of the Board, effective November 12, 2024. Collegium Pharmaceutical, Inc reported in an 8-K filed November 7, 2024 that Vikram Karnani was appointed President and Chief Executive Officer, effective November 12, 2024. The proxy statement of Collegium Pharmaceutical, Inc reports total compensation of $1,715,846 for Vikram Karnani in fiscal 2025, including a base salary of $875,000. Disclosed compensation is on record for 4 fiscal years. Vikram Karnani has spoken on 6 earnings calls and 5 other investor events across 1 company, most recently for Collegium Pharmaceutical, Inc on September 16, 2026. Collegium Pharmaceutical, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Collegium Pharmaceutical, Inc includes Gino Santini (Chairman and Board Member), David Dieter (General Counsel), Shirley Kuhlmann (General Counsel) and 7 others.
“Each of Rita Balice-Gordon, Garen Bohlin, John Fallon, John Freund, Vikram Karnani, Nancy Lurker, Carlos Paya and Gino Santini was elected by the Company's shareholders as Directors to hold office until the 2026 Annual Meeting of Shareholders.”
“Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board and the size of the Board will increase to eight directors.”
“Before I start with the presentation, I'd like to remind everyone that during this presentation, I will be making forward-looking statements and discussing non-GAAP metrics please refer to the risk factors and non-GAAP reconciliations discussed in our latest sec filings thank you for the opportunity to introduce you…”
“Give you a little bit of background on Collegium. We're a, we'll describe ourselves as a dynamic, growing biopharmaceutical company focusing on improving the lives of people living with serious and often misunderstood conditions.”
“Collegium is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex CNS and pain conditions.”
“So Collegium today is a strong commercially focused biopharmaceutical company. We have two – we primarily operate in two areas. Our legacy, which is in pain management, responsible pain management, which has three products, and ADHD, which now, as of very recently, have two complementary medicines across the board.”
“At Collegium, we are building a leading diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.”
2024-11-12–present
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2024-11-12–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Collegium Pharmaceutical, Inc (COLL) | President and Chief Executive Officer | $875,000 | $1,715,846 |
| 2024 | Collegium Pharmaceutical, Inc (COLL) | President and Chief Executive Officer | $97,596 | $10,780,125 |
| 2023 | Collegium Pharmaceutical, Inc (COLL) | President and Chief Executive Officer | — | — |
| 2022 | Collegium Pharmaceutical, Inc (COLL) | President and Chief Executive Officer | — | — |
